Organogenesis announces favorable court ruling dismissing securities fraud case

Organogenesis Holdings announced that on March 29, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted. “We are very pleased with the Court’s decision,” said Lori Freedman, Chief Administrative and Legal Officer for Organogenesis. “We are happy to have this behind us so we can continue to focus on our mission to substantially improve patient outcomes while lowering the overall cost of care.”